European Regulators Uphold Valproate Precautions Amid Unclear Paternal Risk

The European Medicines Agency's safety committee has concluded its review of valproate, noting inconsistent evidence regarding a potential link between paternal use and neurodevelopmental disorders in offspring. Despite the uncertainty, the agency will continue to enforce existing safety measures for valproate and related medications. This decision underscores a cautious approach to drug safety.